Citadel Advisors
ACER

Citadel Advisors’s Acer Therapeutics Inc ACER Stock Holding History

Citadel Advisors’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,700
Closed -$1.57K – 15433
2023
Q2 		$1.57K Sell
1,700
-300
-15% -$266 ﹤0.01% 13908
2023
Q1 		$1.52K Sell
2,000
-39,200
-95% -$77.3K ﹤0.01% 14287
2022
Q4 		$103K Buy
41,200
+1,300
+3% +$2.23K ﹤0.01% 11170
2022
Q3 		$55K Sell
39,900
-14,600
-27% -$21.1K ﹤0.01% 11563
2022
Q2 		$69K Buy
+54,500
New +$114K ﹤0.01% 11725
2021
Q2 		– Sell
-18,600
Closed -$58K – 14671
2021
Q1 		$58K Buy
+18,600
New +$63.2K ﹤0.01% 12830

Other funds holding ACER

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Citadel Advisors's ACER Position: Q3 2023 in Review

Citadel Advisors sold out of Acer Therapeutics Inc (ACER) in Q3 2023, closing a stake of 3,359 shares — an estimated $3.1K sold.

Citadel Advisors first reported a position in ACER in Q3 2013 and held it in 13 quarters. The position peaked at $191K in Q1 2021. 31 funds tracked by Wall St. Rank hold ACER as of Q3 2023.

  • Citadel Advisors reported no remaining Acer Therapeutics Inc position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 3,359 Acer Therapeutics Inc shares in Q3 2023, an estimated $3.1K.
  • Citadel Advisors first reported a position in Acer Therapeutics Inc in Q3 2013 and held it in 13 quarters.
  • Citadel Advisors's Acer Therapeutics Inc position peaked at $191K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.